ArticleJournal of arrhythmia2019
Differences in outcomes between oral anticoagulation "new starters" and "switchers" in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials.
Article in Journal of arrhythmia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore differences in outcomes between dose-adjusted vitamin K antagonists (VKAs) "new starters" and "switchers" in patients with nonvalvular atrial fibrillation (AF).
methodsA post hoc analysis was performed to assess the outcome differences between VKA "new starters" and "switchers" in AF patients using pooled individual patient data of AMADEUS and BOREALIS trials.
resultsA total of 4169 AF patients were included in the present analysis, which included 1383 "VKA new starters" and 2786 "VKA switchers". VKA new starters had higher crude rates of all-cause mortality (
conclusionsIn this post hoc analysis of clinical trial patients with AF, "new starters" and "switchers" for VKA initiation had nonstatistically significant rates of trial-adjudicated thromboembolism, major bleeding, and all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.